Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets

• Published in: Archivos españoles de urología Vol. 66; no. 5; pp. 453 - 462
• Main Authors: Mellado, Begoña, Marin Aguilera, Mercedes, Pereira, Maria Veronica
• Format: Journal Article
• Language: English
• Published: Spain 01-06-2013
• Subjects: Androgen Antagonists - pharmacology; Androgen Antagonists - therapeutic use; Androgens - biosynthesis; Animals; Disease Progression; Humans; Male; Molecular Biology; Orchiectomy; Prostatic Neoplasms - genetics; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - surgery; Receptors, Androgen - drug effects; Receptors, Androgen - genetics; Signal Transduction - physiology; Tubulin - drug effects
• ISSN: 1576-8260

Prostate cancer cells express the androgen receptor (AR) and need the presence of androgens to survive. Androgen suppression is the gold standard first-line therapy for metastatic disease. Almost all prostate cancer patients initially respond to hormonal therapy, but most of them gradually develop castration-resistant progression. Recent evidence has shown that progression at the castration resistant prostate cancer (CRPC) stage is often mediated by AR signalling. Importantly, subsequent AR androgen inhibition, by abiraterone acetate or enzalutamide, has shown to improve patients' survival. Several mechanisms that enhance AR signalling in an androgen-depleted environment have been elucidated:(1) AR mutations that allow activation by low androgen levels or by other endogenous steroids, (2) AR amplification and/or overexpression,(3)increased local intracrine synthesis of androgens, (4) changes in AR cofactors and (5) cross-talk with cytokines and growth factors. Today, there are under development a number of novel agents targeting the AR signaling pathway. This article reviews the postulated mechanisms of AR-driven resistance to androgen suppression that have contributed to the development of new hormonal therapeutic strategies in prostate cancer.